BELOIT, Wisc. — BIOEMTECH has entered into a strategic supply agreement with NorthStar Medical Radioisotopes to secure a reliable source of Actinium-225 for use in preclinical radiopharmaceutical research conducted by BIOEMTECH customers.
Under the agreement, BIOEMTECH customers will gain consistent access to Actinium-225, an alpha-emitting isotope widely used in the development and evaluation of targeted radiotherapeutics. The companies said the arrangement is intended to help accelerate preclinical radiopharmaceutical programs by reducing supply constraints and ensuring timely access to high-quality isotope material.
Actinium-225 has become increasingly important in early-stage radiopharmaceutical research, but limited availability has created challenges for many research programs. The supply agreement is designed to address this bottleneck by providing predictable, compliant access to the isotope for a broad range of investigational studies compatible with BIOEMTECH’s preclinical imaging platforms.
“We are pleased to partner with NorthStar Isotopes to strengthen access to Ac-225 for the preclinical research community,” said Maritina Rouchota, Ph.D., Chief Quality Officer of BIOEMTECH. “Reliable isotope supply is a major bottleneck in early radiopharmaceutical development. This agreement enables our customers to run more predictable, higher-impact studies using our imaging platforms.”
NorthStar said the collaboration supports its broader effort to expand the availability of critical radioisotopes for the growing radiopharmaceutical market.
“NorthStar is committed to expanding Ac-225 supply for the growing radiopharmaceutical market,” said Frank Scholz, President and CEO of NorthStar Medical Radioisotopes. “Working with BIOEMTECH to support preclinical researchers aligns with our mission to advance global access to radiopharmaceuticals with dependable isotope supply that meets quality and regulatory standards.”
The agreement includes regular, scheduled deliveries of Actinium-225 tailored to preclinical research timelines, with material supplied under validated procedures that meet applicable regulatory and transport requirements. Initial deliveries are expected to begin in the first quarter of 2026, with volumes scalable based on research demand.
BIOEMTECH said its customers and partners will be able to request Actinium-225 through the company’s existing ordering channels, while NorthStar will provide isotope-specific documentation and handling guidance to support laboratory safety and study reproducibility.
